ENTEAVENIR 1 MG

Država: Izrael

Jezik: engleski

Izvor: Ministry of Health

Aktivni sastojci:

ENTECAVIR AS MONOHYDRATE

Dostupno od:

BIOAVENIR LTD, ISRAEL

ATC koda:

J05AF10

Farmaceutski oblik:

FILM COATED TABLETS

Sastav:

ENTECAVIR AS MONOHYDRATE 1 MG

Administracija rute:

PER OS

Tip recepta:

Required

Proizveden od:

HETERO LABS LIMITED, INDIA

Područje terapije:

ENTECAVIR

Terapijske indikacije:

Enteavenir is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: - Compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (ALT) levels. - Decompensated liver disease.

Datum autorizacije:

2021-03-21

Uputa o lijeku

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS (PREPARATIONS( - 1986
This medicine is dispensed with a doctor’s prescription only
ENTEAVENIR 0.5 MG
film-coated tablets
ENTEAVENIR 1 MG
film-coated tablets
COMPOSITION:
Each film-coated tablet of Enteavenir 0.5 mg contains:
entecavir (as monohydrate) 0.5 mg
Each film-coated tablet of Enteavenir 1 mg contains:
entecavir (as monohydrate) 1 mg
For information on inactive ingredients, see chapter 6 - ‘Additional
information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains concise information about this
medicine. If you have any further questions, consult your doctor
or pharmacist.
This medicine has been prescribed to treat your illness. Do not
pass it on to others. It may harm them, even if it seems to you that
their illness is similar to yours.
This medicine is intended for adults.
1. WHAT IS THIS MEDICINE INTENDED FOR?
Enteavenir is an anti-viral medicine used to treat chronic hepatitis
caused by hepatitis B virus (HBV) infection in adults with:
Compensated liver disease and evidence of active viral replication,
and persistently elevated serum alanine aminotransferase (ALT)
levels.
Decompensated liver disease.
Chronic hepatitis B virus (HBV) infection can lead to damage to
the liver. Enteavenir reduces the virus levels in your body and
thus improves the condition of the liver.
THERAPEUTIC GROUP:
Nucleosides and nucleotides of the reverse transcriptase enzyme
inhibitor group.
2. BEFORE USING THIS MEDICINE:
DO NOT USE THIS MEDICINE IF:
You are sensitive (allergic) to the active ingredient entecavir
or to any of the other ingredients in this medicine (see chapter
6 - ‘Additional information’(.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE:
Taking Enteavenir will not stop you from infecting other people
with hepatitis B virus (HBV) through sexual contact or body
fluids (including blood contamination). Therefore, it is important
to take appropriate precautions to prevent others from becoming
infected